26 May 2020 Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
26 May 2020 Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies
26 May 2020 FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
26 May 2020 Immunocore announces dosing of first patient with fourth ImmTAC®
26 May 2020 argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
26 May 2020 Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
23 May 2020 Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
22 May 2020 Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
21 May 2020 Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5
20 May 2020 Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
19 May 2020 FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer
18 May 2020 First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar
18 May 2020 Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
18 May 2020 Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
18 May 2020 Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
18 May 2020 ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
16 May 2020 STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
16 May 2020 Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics
16 May 2020 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1%
15 May 2020 Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study
15 May 2020 Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
15 May 2020 BioInvent expands anti-TNFR2 program by selecting second monoclonal antibody for further development
14 May 2020 Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
14 May 2020 European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
14 May 2020 Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up